Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X3E4, Canada
NCT Number: NCT05896150
Intercostal cryoanalgesia is a technique that allows extensive and prolonged analgesia of the hemithorax. The aim of this study is to demonstrate the efficacy of intercostal cryoanalgesia as an adjunct to a single-injection paravertebral block for the management of acute thoracic pain after VATS lung resection surgery.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Montreal, Quebec, H2X3E4, Canada
VATS lung resection is associated with a high incidence of moderate to severe acute thoracic pain. In the postoperative period, optimal analgesia may facilitate recovery, lead to higher patient satisfaction, and lower postoperative complications.
Regional analgesia techniques are usually recommended for VATS, and the paravertebral block is often used. However, the duration of the paravertebral block is short (6 to 24 hours), and prolongation of the effect requires the placement of a paravertebral catheter and local anesthetic infusion into the paravertebral space. At our institution, patients with VATS lung resections are often discharged home 24-48 hours after surgery.
Intercostal cryoanalgesia has an onset of about 12 hours, which coincides with the weaning of the single-injection paravertebral block. Analgesia is usually prolonged over several weeks, does not require catheter placement, and is not associated with hemodynamic side effects. These characteristics may allow rapid recovery and safe home discharge after VATS lung resection.
The aim of this study is to demonstrate the efficacy of intercostal cryoanalgesia as an adjunct to a single-injection paravertebral block for the management of acute thoracic pain after VATS lung resection surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
Paravertebral block with Bupivacaine 0.5%
Time frame: 24 hours
Numerical Rating Scale (NRS) score : scale 0 (no pain) to 10 (worst)
Time frame: 1 hour, 6 hours, 12 hours, 18 hours, 24 hours, 48 hours and 7 days
Numerical Rating Scale (NRS) score : scale 0 (no pain) to 10 (worst)
Time frame: 1 hour, 6 hours, 12 hours, 18 hours, 48 hours and 7 days
Numerical Rating Scale (NRS) score : scale 0 (no pain) to 10 (worst)
Time frame: 7 days
Using a Patient Controlled Analgesia (PCA) pump for the first 24 hours, then daily
Time frame: Preoperative and 48 hours postoperative
QoR-15 is a score evaluating the quality of recovery after surgery and anesthesia
Time frame: 24 hours
Evaluation of the dermatomal levels of hypoesthesia using a Von Frey monofilament
Time frame: 7 days
Evaluation for nausea (yes or no)
Time frame: 30 days
Total time between the end of surgery and prescription for hospital discharge
Time frame: 7 days
Using the Ramsay score (1 to 6)
Time frame: 7 days
Evaluation for vomiting (yes or no)
Time frame: 7 days
Evaluation for pruritus (yes or no)
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Intercostal Cryoanalgesia for Management of Acute Postoperative Pain Following Video-assisted Thoracoscopic Lung Cancer Resection
Acronym: CRYO-VATS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07063602
Paravertebral Block, Thoracic Surgery
Montreal, Quebec, Canada
View Trial DetailsNCT04962581
Capnography, Double-Lumen Tube
Québec, Quebec, Canada
View Trial DetailsNCT02919267
Lung Collapse, Lung Diseases
Québec, Canada
View Trial DetailsNCT07100509
Blood Loss, Surgical, Cardiovascular Diseases
View Trial Details